Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus
- PMID: 20804372
- DOI: 10.1086/656235
Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus
Abstract
Background: Variation in the IL28B gene is associated with sustained virologic response (SVR) to pegylated interferon plus ribavirin in hepatitis C virus (HCV)-monoinfected patients with genotype 1. Data on other genotypes and on patients coinfected with human immunodeficiency virus (HIV) and HCV are more limited. We aimed to assess the predictive ability of variations in the single-nucleotide polymorphism rs12979860 for SVR in HIV/HCV-coinfected patients, regardless of HCV genotype.
Methods: The rs12979860 genotype was determined by polymerase chain reaction in 154 patients who had received therapy against HCV with pegylated interferon plus ribavirin.
Results: rs12979860 genotype was TT in 20 patients (13%), TC in 66 patients (43%), and CC in 68 patients (44%). Rates of SVR in patients with genotype CC and in those with genotype TC or TT, according to HCV genotype, were, respectively, 50% and 17% (P < .001) in patients with genotype 1, 80% and 25% (P = .027) in patients with genotype 4, and 93% and 77% (P = .115) in patients with genotype 3. The median (interquartile range) low-density lipoprotein cholesterol level in patients with rs12979860 CC was 89 mg/dL (73-120 mg/dL) versus 75 mg/dL (55-91 mg/dL) (P = .001) in those with TC or TT. Independent predictors of SVR were HCV genotype 2-3 (odds ratio [OR], 13.98; 95% confidence interval [CI], 4.87-40.1; P < .001), rs12979860 CC (OR, 5.05; 95% CI, 2.04-12.5; P < .001), baseline plasma HCV RNA load of < or =600,000 IU/mL (OR, 1.99; 95% CI, 1.18- 3.34; P = .009), and female sex (OR, 4.28; 95% CI, 1.08-16.96; P = .039).
Conclusions: IL28B gene variations independently predict SVR in HIV/HCV-coinfected patients with HCV genotype 1 and non-genotype 1 HCV infection. The association between rs12979860 and plasma low-density lipoprotein cholesterol suggests that the system low-density lipoprotein ligand/receptor might be involved in the effect of this genotype.
Similar articles
-
IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.AIDS. 2011 May 15;25(8):1025-33. doi: 10.1097/QAD.0b013e3283471cae. AIDS. 2011. PMID: 21505315 Free PMC article.
-
Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.Liver Int. 2014 Jul;34(6):890-5. doi: 10.1111/liv.12321. Epub 2013 Oct 14. Liver Int. 2014. PMID: 24102823
-
Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load.J Hepatol. 2012 Apr;56(4):788-94. doi: 10.1016/j.jhep.2011.11.008. Epub 2011 Dec 13. J Hepatol. 2012. PMID: 22173157
-
IL28B rs12980275 variant as a predictor of sustained virologic response to pegylated-interferon and ribavirin in chronic hepatitis C patients: A systematic review and meta-analysis.Clin Res Hepatol Gastroenterol. 2015 Oct;39(5):576-83. doi: 10.1016/j.clinre.2015.01.009. Epub 2015 Mar 10. Clin Res Hepatol Gastroenterol. 2015. PMID: 25769643
-
Influence of Host and Viral Factors on Patients with Chronic Hepatitis C Virus Genotype 6 Treated with Pegylated Interferon and Ribavirin: A Systematic Review and Meta-Analysis.Intervirology. 2015;58(6):373-81. doi: 10.1159/000444366. Epub 2016 Mar 25. Intervirology. 2015. PMID: 27010195
Cited by
-
PharmGKB summary: peginterferon-α pathway.Pharmacogenet Genomics. 2015 Sep;25(9):465-74. doi: 10.1097/FPC.0000000000000158. Pharmacogenet Genomics. 2015. PMID: 26111151 Free PMC article. No abstract available.
-
Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV/HCV-coinfected patients with pretreatment thrombocytopenia.Eur J Clin Microbiol Infect Dis. 2015 Sep;34(9):1879-84. doi: 10.1007/s10096-015-2426-6. Epub 2015 Jun 27. Eur J Clin Microbiol Infect Dis. 2015. PMID: 26115631
-
The IL-28 genotype: how it will affect the care of patients with hepatitis C virus infection.Curr Gastroenterol Rep. 2011 Feb;13(1):78-86. doi: 10.1007/s11894-010-0161-9. Curr Gastroenterol Rep. 2011. PMID: 21080244 Review.
-
Prospects for personalizing antiviral therapy for hepatitis C virus with pharmacogenetics.Genome Med. 2011 Feb 8;3(2):8. doi: 10.1186/gm222. Genome Med. 2011. PMID: 21345258 Free PMC article.
-
Danoprevir monotherapy decreases inflammatory markers in patients with chronic hepatitis C virus infection.Antimicrob Agents Chemother. 2011 Jul;55(7):3125-32. doi: 10.1128/AAC.00131-11. Epub 2011 Apr 18. Antimicrob Agents Chemother. 2011. PMID: 21502634 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases